Benzinga | Aug 23, 2021 05:35AM EDT

Credit Suisse Initiates Coverage On Candel Therapeutics with Outperform Rating, Announces Price Target of $15

Credit Suisse analyst Judah Frommer initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Outperform rating and announces Price Target of $15.